Ro 48-8071 fumarate (CAS 189197-69-1)

Ro 48-8071 fumarate, a selective inhibitor of microsomal triglyceride transfer protein (MTP), has emerged as a valuable tool in elucidating the role of lipid metabolism in various physiological processes. By inhibiting MTP, Ro 48-8071 fumarate disrupts the assembly and secretion of very low-density lipoprotein (VLDL) particles in the liver, consequently leading to reduced plasma levels of triglycerides and cholesterol. This mechanism of action has been extensively studied in the context of dyslipidemia and cardiovascular diseases, providing insights into the regulation of lipid homeostasis and the development of novel strategies. Additionally, Ro 48-8071 fumarate has been utilized in research to investigate the pathophysiology of lipid-related disorders, such as non-alcoholic fatty liver disease (NAFLD), hyperlipidemia, and atherosclerosis. Furthermore, its inhibitory effect on MTP has been leveraged to explore its potential as a pharmacological intervention for the treatment of obesity and metabolic syndrome. Through mechanistic studies and experimental models, Ro 48-8071 fumarate continues to contribute to our understanding of lipid metabolism and its implications for human health, offering promising avenues for further research and development.